LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.
Questions? Call our customer API support number 1-(800)-881-8210
After conversion to its active form by phosphatases, tedizolid exerts its antibacterial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of susceptible Gram-positive bacteria. Cross-resistance between other non-oxazolidinone antibacterial drugs is unlikely as it inhibits bacterial protein synthesis through a different mechanism.
There is little patient-to-patient variability in the concentration of tedizolid phosphate in blood, as compared to linezolid. As a result, we expect that tedizolid phosphate will have more predictable drug exposure which may lead to a more uniform efficacy and safety profile across different patients when compared to linezolid.
Tedizolid phosphate is a prodrug that is converted by phosphatases to tedizolid, it’s microbiologically active form. There are no other significant circulating metabolites beyond tedizolid which accounts for approximately 95% of the AUC. It is also unlikely to be metabolized by CYP450 enzymes in the liver.
The most commonly reported adverse effects were nausea, vomiting, diarrhea, nausea, and dizziness. Other reactions that occurred during clinical trials at a rate less than 2% include anemia, tachycardia, blurred vision, oral candidiasis, colitis, decreased white blood cell count, vulvovaginal mycotic infection, paresthesia, hypertension, and urticaria. There are no adequate studies to confirm that tedizolid phosphate is safe to use during pregnancy and should be avoided as it was shown to produce fetal developmental toxicities in mice, rats, and rabbits.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.
Questions? Call our customer API support number 1-(800)-881-8210.
LGM PHARMA
Call Toll-Free: 1-800-881-8210
Corporate Headquarters:
6400 Congress Avenue, Suite 1400
Boca Raton, FL 33487, USA